Hussey Hannah, Vreede Helena, Davies Mary-Ann, Heekes Alexa, Kalk Emma, Hardie Diana, van Zyl Gert, Naidoo Michelle, Morden Erna, Bam Jamy-Lee, Zinyakatira Nesbert, Centner Chad M, Maritz Jean, Opie Jessica, Chapanduka Zivanai, Mahomed Hassan, Smith Mariette, Cois Annibale, Pienaar David, Redd Andrew D, Preiser Wolfgang, Wilkinson Robert, Boulle Andrew, Hsiao Nei-Yuan
Health Intelligence Directorate, Western Cape Government: Health, Cape Town, South Africa.
Metro Health Services, Western Cape Government: Health, Cape Town, South Africa.
PLOS Glob Public Health. 2024 Aug 6;4(8):e0003554. doi: 10.1371/journal.pgph.0003554. eCollection 2024.
In low- and middle-income countries where SARS-CoV-2 testing is limited, seroprevalence studies can help describe and characterise the extent of the pandemic, as well as elucidate protection conferred by prior exposure. We conducted repeated cross-sectional serosurveys (July 2020 -November 2021) using residual samples from patients from Cape Town, South Africa, sent for routine laboratory studies for non-COVID-19 conditions. SARS-CoV-2 anti-nucleocapsid antibodies and linked clinical information were used to investigate: (1) seroprevalence over time and risk factors associated with seropositivity, (2) ecological comparison of seroprevalence between subdistricts, (3) case ascertainment rates, and (4) the relative protection against COVID-19 associated with seropositivity and vaccination statuses. Among the subset sampled, seroprevalence of SARS-CoV-2 in Cape Town increased from 39.19% (95% confidence interval [CI] 37.23-41.19) in July 2020 to 67.8% (95%CI 66.31-69.25) in November 2021. Poorer communities had both higher seroprevalence and COVID-19 mortality. Only 10% of seropositive individuals had a recorded positive SARS-CoV-2 test. Using COVID-19 hospital admission and death data at the Provincial Health Data Centre, antibody positivity before the start of the Omicron BA.1 wave (28 November 2021) was strongly protective for severe disease (adjusted odds ratio [aOR] 0.15; 95%CI 0.05-0.46), with additional benefit in those who were also vaccinated (aOR 0.07, 95%CI 0.01-0.35). The high population seroprevalence in Cape Town was attained at the cost of substantial COVID-19 mortality. At the individual level, seropositivity was highly protective against subsequent infections and severe COVID-19 disease. In low-income communities, where diagnostic testing capacity is often limited, surveillance systems dependent on them will underestimate the true extent of an outbreak. Rapidly conducted seroprevalence studies can play an important role in addressing this.
在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)检测受限的低收入和中等收入国家,血清流行率研究有助于描述和刻画大流行的程度,以及阐明既往暴露所提供的保护作用。我们利用南非开普敦患者的剩余样本进行了重复横断面血清学调查(2020年7月至2021年11月),这些样本被送去进行针对非新冠疾病的常规实验室检测。使用SARS-CoV-2抗核衣壳抗体及相关临床信息来调查:(1)随时间变化的血清流行率及与血清阳性相关的危险因素,(2)各分区之间血清流行率的生态学比较,(3)病例确诊率,以及(4)与血清阳性和疫苗接种状态相关的针对新冠的相对保护作用。在抽样的子集中,开普敦SARS-CoV-2的血清流行率从2020年7月的39.19%(95%置信区间[CI] 37.23 - 41.19)增至2021年11月的67.8%(95%CI 66.31 - 69.25)。较贫困社区的血清流行率和新冠死亡率均更高。只有10%的血清阳性个体有SARS-CoV-2检测呈阳性的记录。利用省级卫生数据中心的新冠住院和死亡数据,在奥密克戎BA.1毒株浪潮开始前(2021年11月28日)抗体阳性对重症具有很强的保护作用(调整优势比[aOR] 0.15;95%CI 0.05 - 0.46),在同时接种疫苗的人群中还有额外益处(aOR 0.07,95%CI 0.01 - 0.35)。开普敦较高的人群血清流行率是以大量的新冠死亡为代价实现的。在个体层面,血清阳性对后续感染和新冠重症具有高度保护作用。在低收入社区,诊断检测能力往往有限,依赖这些检测的监测系统会低估疫情的真实规模。快速开展的血清流行率研究可在解决这一问题方面发挥重要作用。